Related Experiment Video
Updated: Dec 28, 2025

Surgical Technique for the Implantation of a Biomimetic Artificial Intervertebral Disc in a Goat Animal Model
Published on: October 10, 2025
Comparison of M6-C and Mobi-C cervical total disc replacement for cervical degenerative disc disease in adults
Nicholas Hui1, Kevin Phan1, Jack Kerferd1
1NeuroSpine Surgery Research Group (NSURG), The University of New South Wales, Sydney, NSW, Australia.
Background:
Cervical total disc replacement (CTDR) is complicated by adjacent segment degeneration (ASD). Since non-physiological spine kinematics after CTDR was postulated to cause ASD, M6-C prosthesis has been developed to better replicate the natural kinematics of the intervertebral disc. This retrospective cohort study aims to compare the short-term outcomes between patients receiving either the M6-C or Mobi-C prostheses.
Methods:
Patients who had refractory radiculopathy and/or myelopathy secondary to cervical degenerative disc disease and underwent CTDR between March 2004 and April 2017 were included. All CTDRs were performed by a single surgeon at a single institution. Self-reported clinical outcomes and radiological parameters were evaluated at baseline and final follow-up between March 2004 and April 2018.
Results:
Sixty-two patients with greater than 1-year follow-up or who developed HO within 12 months of surgery, were included in the study. The mean radiological follow-up was 29.0 months (3-84 months), which includes 7 patients with less than 12 months follow-up who also developed HO. The changes in clinical and radiological measures were comparable between M6-C and Mobi-C prostheses. Thirty-seven out of 52 spinal segments (71.2%) and 10 out of 16 spinal segments (62.5%) developed HO in M6-C and Mobi-C group respectively. There was no significant difference in the rate of HO between the two groups.
Conclusions:
No short-term differences were found in clinical or radiological outcomes between patients who received either the M6-C or Mobi-C prosthesis. Further randomized trials with a long-term follow-up period are warranted to determine the safety and efficacy of M6-C prosthesis.

